|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 158.00 GBX | +3.27% |
|
+8.22% | +23.44% |
| 07-29 | Diaceutics PLC Reports Revenue Results for the Half Year Ended 30 June 2026 | CI |
| 06-02 | Diaceutics PLC, 2025 Earnings Call, May 26, 2026 |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 13.94M | 19.5M | 23.7M | 32.16M | 38.44M | |||||
Total Revenues | 13.94M | 19.5M | 23.7M | 32.16M | 38.44M | |||||
Cost of Goods Sold, Total | 3.21M | 2.76M | 3.99M | 3.89M | 6.96M | |||||
Gross Profit | 10.73M | 16.74M | 19.71M | 28.27M | 31.48M | |||||
Selling General & Admin Expenses, Total | 10.38M | 16.28M | 22.78M | 30.74M | 31.69M | |||||
Other Operating Expenses | -195K | -114K | -60K | -17K | -255K | |||||
Other Operating Expenses, Total | 10.18M | 16.17M | 22.72M | 30.72M | 31.44M | |||||
Operating Income | 550K | 575K | -3.02M | -2.46M | 43K | |||||
Interest Expense, Total | -88K | -120K | -66K | -54K | -58K | |||||
Interest And Investment Income | - | 111K | 646K | 601K | 317K | |||||
Net Interest Expenses | -88K | -9K | 580K | 547K | 259K | |||||
Other Non Operating Income (Expenses) | - | -2K | - | - | - | |||||
EBT, Excl. Unusual Items | 462K | 564K | -2.44M | -1.91M | 302K | |||||
Restructuring Charges | - | - | - | - | - | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | 462K | 564K | -2.44M | -1.91M | 302K | |||||
Income Tax Expense | -99K | -160K | -692K | -205K | 205K | |||||
Earnings From Continuing Operations | 561K | 724K | -1.75M | -1.7M | 97K | |||||
Net Income to Company | 561K | 724K | -1.75M | -1.7M | 97K | |||||
Net Income - (IS) | 561K | 724K | -1.75M | -1.7M | 97K | |||||
Net Income to Common Incl Extra Items | 561K | 724K | -1.75M | -1.7M | 97K | |||||
Net Income to Common Excl. Extra Items | 561K | 724K | -1.75M | -1.7M | 97K | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.01 | 0.01 | -0.02 | -0.02 | 0 | |||||
Basic EPS - Continuing Operations | 0.01 | 0.01 | -0.02 | -0.02 | 0 | |||||
Basic Weighted Average Shares Outstanding | 83.94M | 84.15M | 84.23M | 84.45M | 84.58M | |||||
Net EPS - Diluted | 0.01 | 0.01 | -0.02 | -0.02 | 0 | |||||
Diluted EPS - Continuing Operations | 0.01 | 0.01 | -0.02 | -0.02 | 0 | |||||
Diluted Weighted Average Shares Outstanding | 84.94M | 86.09M | 84.23M | 84.45M | 85.13M | |||||
Normalized Basic EPS | 0 | 0 | -0.02 | -0.01 | 0 | |||||
Normalized Diluted EPS | 0 | 0 | -0.02 | -0.01 | 0 | |||||
Payout Ratio | - | - | - | - | - | |||||
Supplemental Items | ||||||||||
EBITDA | 1.52M | 2.08M | 102K | 552K | 4.08M | |||||
EBITA | 1.43M | 1.93M | -59K | 385K | 3.92M | |||||
EBIT | 550K | 575K | -3.02M | -2.46M | 43K | |||||
EBITDAR | - | - | - | - | - | |||||
Effective Tax Rate - (Ratio) | -21.43 | -28.37 | 28.38 | 10.74 | 67.88 | |||||
Current Domestic Taxes | -535K | -670K | 314K | -191K | - | |||||
Current Foreign Taxes | 83K | 336K | 798K | 989K | 1.3M | |||||
Total Current Taxes | -452K | -334K | 1.11M | 798K | 1.3M | |||||
Total Deferred Taxes | 353K | 174K | -1.8M | -1M | -1.1M | |||||
Normalized Net Income | 289K | 352K | -1.52M | -1.19M | 189K | |||||
Interest on Long-Term Debt | 88K | 122K | 66K | 54K | 58K | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | - | - | - | - | - | |||||
General and Administrative Expenses | 10.38M | 16.28M | 22.78M | 30.74M | 31.69M | |||||
Research And Development Expense From Footnotes | - | - | - | - | - | |||||
Net Rental Expense, Total | - | - | - | - | - | |||||
Imputed Operating Lease Interest Expense | - | - | - | - | - | |||||
Imputed Operating Lease Depreciation | - | - | - | - | - | |||||
Stock-Based Comp., G&A Exp. (Total) | 428K | - | - | - | - | |||||
Stock-Based Comp., Other (Total) | - | 621K | 538K | 1.26M | 1.13M | |||||
Total Stock-Based Compensation | 428K | 621K | 538K | 1.26M | 1.13M |
- Stock Market
- Stocks
- DXRX Stock
- Financials Diaceutics PLC
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















